The Tasigna lawsuit is intended to fight for leukemia survivors who were on Tasigna as a treatment for blood cancer and suffered damage to their arteries. Recent research has suggested there may be a link between the medication and atherosclerosis, a fairly common yet dangerous disease that causes plaque buildup in patients’ arteries and restricting normal blood flow.
Tasigna is a drug that is primarily used to treat a blood cancer known as “chronic myeloid leukemia” or CML. Lawyers and critics of the medication’s side effects in patients argue that Novartis, the manufacturer of the Tasigna, failed to warn doctors and patients in the United States of the risk of atherosclerosis, noting that doctors and patients were properly warned in Canada. Patients who have used the medication and experienced arterial disease, heart failure, fatigue, or have been diagnosed with atherosclerosis may qualify for financial compensation. If you or a loved one were on the medication Tasigna for the blood cancer known as Chronic Myeloid Leukemia (CML) and suffered complications associated with atherosclerosis, including plaque buildup and restricted blood circulation, contact Schmidt National Law Group for more information about this lawsuit.
Tasigna is an oral medication that is manufactured by Novartis and intended for patients diagnosed with chronic myeloid leukemia, a blood cancer. Tasigna is also sometimes referred to by its generic name. “nilotinib.” Chronic Myeloid Leukemia causes a patient’s bone marrow to make too many white blood cells. CML is a treatable cancer that can be managed with the proper medication, but may become a chronic disease if it is not treated properly. According to the National Cancer Institute, there are approximately 9000 new reported cases of CML in the United States annually and approximately 1000 deaths.
Recent research has suggested there may be a link between the drug Tasigna and atherosclerosis, a disease where plaque can build up in the arteries and restrict blood flow. Although the effects of atherosclerosis are typically associated with the heart, it can affect any of the body’s major arteries arteries, including the brain, legs, and kidneys. The lack of adequate blood circulation in or near the heart can lead to other dangerous diseases like coronary artery disease, heart disease, and heart failure. Restricting blood to patients’ arms and legs can promote infections and tissue damage and in some extreme cases require amputation.
According to the European Hematology Association, “evidence suggests that [Tasigna] nilotinib has a propensity to increase the risk of occlusive arterial events, especially in patients with pre-existing cardiovascular risk factors.”
In a December 2015 article published in Cardio-Oncology, several reports outline a possible correlation between Tasigna patients and risky cardiovascular side effects, including arterial disease and atherosclerosis.
Despite all the mounting evidence and links between the leukemia medication and its effects on patients’ arteries, blood flow, heart and general circulatory and vascular systems, Tasigna has not yet been recalled in the United States. Many lawsuits, however, make the claim that the manufacturer of Tasigna, Novartis, was aware of these risks and failed to properly warn doctors and patients in the US. The Canadian healthcare system has published a safety warning in Canada that the usage of the medication may increase the patient’s risk of developing atherosclerosis and other arterial disease. Furthermore, Health Canada published multiple safety alerts warning that, “cases of atherosclerosis-related conditions have been reported during clinical trials and post marketing experience with the use of Tasigna.” Healthcare professionals and their patients received adequate warning in Canada about the drugs link to atherosclerosis and other related diseases.
If you or a loved one were diagnosed with Chronic Myeloid Leukemia (CML), were on the medication Tasigna and suffered complications associated with atherosclerosis, including plaque buildup and restricted blood circulation, contact Schmidt National Law Group for more information about this lawsuit.